Algert Global LLC Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Algert Global LLC lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 45.0% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,342 shares of the company’s stock after buying an additional 3,832 shares during the quarter. Algert Global LLC’s holdings in CRISPR Therapeutics were worth $667,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of CRSP. Scientech Research LLC boosted its stake in shares of CRISPR Therapeutics by 181.6% in the second quarter. Scientech Research LLC now owns 24,323 shares of the company’s stock worth $1,314,000 after acquiring an additional 15,686 shares during the period. Armistice Capital LLC boosted its stake in CRISPR Therapeutics by 3.3% in the 2nd quarter. Armistice Capital LLC now owns 198,357 shares of the company’s stock worth $10,713,000 after purchasing an additional 6,357 shares during the period. Marshall Wace LLP purchased a new stake in CRISPR Therapeutics during the 2nd quarter valued at approximately $10,078,000. Farallon Capital Management LLC bought a new stake in shares of CRISPR Therapeutics during the second quarter valued at approximately $28,625,000. Finally, Bank of Montreal Can raised its position in shares of CRISPR Therapeutics by 26.3% during the second quarter. Bank of Montreal Can now owns 7,556 shares of the company’s stock valued at $408,000 after buying an additional 1,574 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Needham & Company LLC dropped their target price on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Stifel Nicolaus reduced their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Truist Financial dropped their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, Royal Bank of Canada cut their price target on CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating for the company in a report on Friday. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $75.19.

CRISPR Therapeutics Stock Up 1.0 %

CRSP opened at $45.37 on Friday. The stock has a market cap of $3.85 billion, a P/E ratio of -16.68 and a beta of 1.68. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10. The business has a fifty day moving average of $48.17 and a 200 day moving average of $54.95.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, August 5th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. During the same quarter in the prior year, the firm earned ($0.98) EPS. The firm’s revenue for the quarter was down 99.3% compared to the same quarter last year. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.